Small molecule · Modulator of voltage-gated sodium channel, cyclooxygenase-1 (PTGS1) and cyclooxygenase-2 (PTGS2) · developed by Heron Theraps
Bupivacaine and meloxicam is an extended-release fixed-ratio combination of a local anesthetic and a low-dose NSAID, incorporated in a bioerodible polymer. Bupivacaine blocks nerve impulse generation and conduction, while meloxicam inhibits cyclooxygenase (COX-1 and COX-2) and reduces prostaglandin synthesis. It is studied for acute postoperative pain.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Apr 20, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05863221 | Phase 4 | Post Operative Pain, Acute | Unknown | HRTX |
| NCT05109312 | Phase 4 | Analgesia | Active not recruiting | HRTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
AnalgesiaBariatric Surgery CandidatePost Operative Pain, AcutePostoperative Pain
Updated Nov 15, 2026. Something wrong or missing? Report it on the HRTX page.
See HRTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
HRTX catalysts and pipeline →